Current Management of Refractory Germ Cell Tumors

[21] Chevreau C(2005)Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study Neoplasma. 52 497-501

[22] Geoffrois L(1989)Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation J Clin Oncol 7 932-939

[23] Bui NB(1992)Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue Ann Intern Med 117 124-128

[24] Pény J(1992)High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol J Clin Oncol 10 558-563

[25] Caty A(1995)Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison J Clin Oncol 13 1328-1335

[26] Delva R(1994)High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group J Clin Oncol 12 1223-1231

[27] Biron P(1996)High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity J Clin Oncol 14 1098-1105

[28] Fizazi K(2001)Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer J Clin Oncol 19 81-88

[29] Bouzy J(2012)Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial J Clin Oncol 30 800-805

[30] Droz JP(2017)High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience J Clin Oncol 35 1096-1102

[21] Chevreau C(2005)Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study Neoplasma. 52 497-501

[22] Geoffrois L(1989)Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation J Clin Oncol 7 932-939

[23] Bui NB(1992)Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue Ann Intern Med 117 124-128

[24] Pény J(1992)High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol J Clin Oncol 10 558-563

[25] Caty A(1995)Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison J Clin Oncol 13 1328-1335

[26] Delva R(1994)High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group J Clin Oncol 12 1223-1231

[27] Biron P(1996)High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity J Clin Oncol 14 1098-1105

[28] Fizazi K(2001)Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer J Clin Oncol 19 81-88

[29] Bouzy J(2012)Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial J Clin Oncol 30 800-805

[30] Droz JP(2017)High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience J Clin Oncol 35 1096-1102